Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence

• Authors: LÁZNIČKOVÁ Petra; KEPÁK Tomáš; HORTOVÁ KOHOUTKOVÁ Marcela; HORVÁTH Luděk; SHEARDOVÁ Kateřina; MARCINIAK Rafał; VACCA Carmine; SIKLOVA Michaela; ZELANTE Teresa; ROSSMEISLOVA Lenka; KŘENOVÁ Zdenka; ŠTĚRBA Jaroslav; BENDICKOVA Kamila; FRIČ Jan
• Year of publication: 2020
• Type: Article in Periodical
• Magazine / Source: EUROPEAN JOURNAL OF IMMUNOLOGY
• MU Faculty or unit: Faculty of Medicine
• Web: https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048541
• Doi: http://dx.doi.org/10.1002/eji.202048541
• Keywords: adverse late effects; childhood; immune recovery; immunosenescence; neuroblastoma
• Description: Neuroblastoma survivors show signs of immunosenescence early after therapy in CD8(+)T cell compartment and elevated plasma TNF-alpha but in later follow-up immune recovery comes into play. Whether the recovery phenotype is long lasting or transient remains to be elucidated, however, late adverse effects often occur in childhood cancer survivors.

Related projects

• Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medicine" a "N-of-1 clinical trials"